Celsion Corporation/$IMNN
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX
About Celsion Corporation
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).
Ticker
$IMNN
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
25
ISIN
US15117N6022
Website
IMNN Metrics
BasicAdvanced
$17M
-
-$1.39
2.14
-
Price and volume
Market cap
$17M
Beta
2.14
52-week high
$3.16
52-week low
$0.37
Average daily volume
23M
Financial strength
Current ratio
0.878
Quick ratio
0.495
Long term debt to equity
135.649
Total debt to equity
223.006
Profitability
EBITDA (TTM)
-18.03
Management effectiveness
Return on assets (TTM)
-107.77%
Return on equity (TTM)
-397.54%
Valuation
Price to book
25.56
Price to tangible book (TTM)
25.56
Price to free cash flow (TTM)
-0.628
Free cash flow yield (TTM)
-159.28%
Free cash flow per share (TTM)
-125.85%
Growth
Earnings per share change (TTM)
-31.23%
3-year earnings per share growth (CAGR)
-29.50%
10-year earnings per share growth (CAGR)
-41.45%
IMNN News
AllArticlesVideos
IMUNON Presents Positive Phase 2 Translational Data of IMNN-001 in Advanced Ovarian Cancer at ESMO Gynaecological Cancers Congress 2025
GlobeNewsWire·2 weeks ago
IMUNON Announces PlaCCine® DNA Vaccine Technology Abstract Selected for Oral Presentation at 10th International Conference on Vaccines Research & Development™
GlobeNewsWire·3 weeks ago
IMUNON Announces Data Presented at ASCO Reinforces Unprecedented Overall Survival in Ovarian Cancer Phase 2 Study
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Celsion Corporation stock?
Celsion Corporation (IMNN) has a market cap of $17M as of July 05, 2025.
What is the P/E ratio for Celsion Corporation stock?
The price to earnings (P/E) ratio for Celsion Corporation (IMNN) stock is 0 as of July 05, 2025.
Does Celsion Corporation stock pay dividends?
No, Celsion Corporation (IMNN) stock does not pay dividends to its shareholders as of July 05, 2025.
When is the next Celsion Corporation dividend payment date?
Celsion Corporation (IMNN) stock does not pay dividends to its shareholders.
What is the beta indicator for Celsion Corporation?
Celsion Corporation (IMNN) has a beta rating of 2.14. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.